Menu
Back to Journals » ClinicoEconomics and Outcomes Research » Volume 7 » default
ClinicoEconomics and Outcomes Research
- View all (752)
- Volume 14, 2022 (33)
- Volume 13, 2021 (90)
- Volume 12, 2020 (70)
- Volume 11, 2019 (71)
- Volume 10, 2018 (77)
- Volume 9, 2017 (77)
- Volume 8, 2016 (73)
- Volume 7, 2015 (64)
- Volume 6, 2014 (53)
- Volume 5, 2013 (59)
- Volume 4, 2012 (41)
- Volume 3, 2011 (19)
- Volume 2, 2010 (16)
- Volume 1, 2009 (9)
Archive: Volume 7, 2015
The impact of ribavirin on real-world adherence rates in hepatitis C patients treated with sofosbuvir plus simeprevir
Walker DR, Juday TR, Manthena SR, Jing Y, Sood V
ClinicoEconomics and Outcomes Research 2015, 7:637-642
Published Date: 17 December 2015
Adjustment of foreign EQ-5D-3L utilities can increase their transferability
Oddershede L, Petersen KD
ClinicoEconomics and Outcomes Research 2015, 7:629-636
Published Date: 15 December 2015
Estimating health-state utility values for patients with recurrent ovarian cancer using Functional Assessment of Cancer Therapy – General mapping algorithms
Hettle R, Borrill J, Suri G, Wulff J
ClinicoEconomics and Outcomes Research 2015, 7:615-627
Published Date: 26 November 2015
Gastrointestinal events and association with initiation of treatment for osteoporosis
Modi A, Siris ES, Tang J, Sajjan S, Sen SS
ClinicoEconomics and Outcomes Research 2015, 7:603-613
Published Date: 25 November 2015
Productivity loss and resource utilization, and associated indirect and direct costs in individuals providing care for adults with schizophrenia in the EU5
Gupta S, Isherwood G, Jones K, Van Impe K
ClinicoEconomics and Outcomes Research 2015, 7:593-602
Published Date: 25 November 2015
Relative cost-effectiveness of using an extensively hydrolyzed casein formula containing the probiotic Lactobacillus rhamnosus GG in managing infants with cow’s milk allergy in Spain
Guest JF, Weidlich D, Mascuñán Díaz JI, Díaz JJ, Ojeda PM, Ferrer-González JP, Gil D, Onrubia I, Rincón Víctor P
ClinicoEconomics and Outcomes Research 2015, 7:583-591
Published Date: 23 November 2015
Doctors commitment and long-term effectiveness for cost containment policies: lesson learned from biosimilar drugs
Menditto E, Orlando V, Coretti S, Putignano D, Fiorentino D, Ruggeri M
ClinicoEconomics and Outcomes Research 2015, 7:575-581
Published Date: 11 November 2015
Variation in hospital resource use and cost among surgical procedures using topical absorbable hemostats
Martyn D, Meckley LM, Miyasato G, Lim S, Riebman JB, Kocharian R, Scaife JG, Rao Y, Corral M
ClinicoEconomics and Outcomes Research 2015, 7:567-574
Published Date: 6 November 2015
Impact of treatment with rosuvastatin and atorvastatin on cardiovascular outcomes: evidence from the Archimedes-simulated clinical trials
Colivicchi F, Sternhufvud C, Gandhi SK
ClinicoEconomics and Outcomes Research 2015, 7:555-565
Published Date: 27 November 2015
The financial burden of sickle cell disease on households in Ekiti, Southwest Nigeria
Olatunya OS, Ogundare EO, Fadare JO, Oluwayemi IO, Agaja OT, Adeyefa BS, Aderiye O
ClinicoEconomics and Outcomes Research 2015, 7:545-553
Published Date: 4 November 2015
The expenditures related to the use of antifungal drugs in patients with hematological cancers: a cost analysis
Gedik H
ClinicoEconomics and Outcomes Research 2015, 7:537-543
Published Date: 3 November 2015
Cost-effectiveness of three echinocandins and fluconazole in the treatment of candidemia and/or invasive candidiasis in nonneutropenic adult patients
Grau S, Pozo JC, Romá E, Salavert M, Barrueta JA, Peral C, Rodriguez I, Rubio-Rodríguez D, Rubio-Terrés C
ClinicoEconomics and Outcomes Research 2015, 7:527-535
Published Date: 13 October 2015
Linezolid for the treatment of hospital-acquired pneumonia in a Chinese tertiary hospital
Lesher BA, Liu Z, Chen Y, Gao X
ClinicoEconomics and Outcomes Research 2015, 7:521-526
Published Date: 9 October 2015
Cost-effectiveness analysis of pregabalin for treatment of chronic low back pain in patients with accompanying lower limb pain (neuropathic component) in Japan
Igarashi A, Akazawa M, Murata T, Taguchi T, Sadosky A, Ebata N, Willke R, Fujii K, Doherty J, Kobayashi M
ClinicoEconomics and Outcomes Research 2015, 7:505-520
Published Date: 7 October 2015
Bias within economic evaluations – the impact of considering the future entry of lower-cost generics on currently estimated incremental cost-effectiveness ratios of a new drug
Guertin JR, Mitchell D, Ali F, LeLorier J
ClinicoEconomics and Outcomes Research 2015, 7:497-503
Published Date: 6 October 2015
Annual impact of scribes on physician productivity and revenue in a cardiology clinic
Bank AJ, Gage RM
ClinicoEconomics and Outcomes Research 2015, 7:489-495
Published Date: 30 September 2015
Estimating the health care burden of prescription opioid abuse in five European countries
Shei A, Hirst M, Kirson NY, Enloe CJ, Birnbaum HG, Dunlop WCN
ClinicoEconomics and Outcomes Research 2015, 7:477-488
Published Date: 15 September 2015
Acceptance of health technology assessment submissions with incremental cost-effectiveness ratios above the cost-effectiveness threshold
Griffiths EA, Hendrich JK, Stoddart SDR, Walsh SCM
ClinicoEconomics and Outcomes Research 2015, 7:463-476
Published Date: 31 August 2015
Review of the cost of venous thromboembolism
Fernandez MM, Hogue S, Preblick R, Kwong WJ
ClinicoEconomics and Outcomes Research 2015, 7:451-462
Published Date: 28 August 2015
AbobotulinumtoxinA in the management of cervical dystonia in the United Kingdom: a budget impact analysis
Abogunrin S, Brand S, Desai K, Dinet J, Gabriel S, Harrower T
ClinicoEconomics and Outcomes Research 2015, 7:441-449
Published Date: 9 September 2015
A narrative review of cost-effectiveness analysis of people living with HIV treated with HAART: from interventions to outcomes
Tse WF, Yang W, Huang W
ClinicoEconomics and Outcomes Research 2015, 7:431-439
Published Date: 11 August 2015
Medical resource utilization for administration of trastuzumab in a New Zealand oncology outpatient setting: a time and motion study
North RT, Harvey VJ, Cox LC, Ryan SN
ClinicoEconomics and Outcomes Research 2015, 7:423-430
Published Date: 29 July 2015
Health and economic outcomes associated with uncontrolled surgical bleeding: a retrospective analysis of the Premier Perspectives Database
Corral M, Ferko N, Hollmann S, Broder MS, Chang E
ClinicoEconomics and Outcomes Research 2015, 7:409-421
Published Date: 22 July 2015
Retrospective analysis of drug utilization, health care resource use, and costs associated with IFN therapy for adjuvant treatment of malignant melanoma
Zhang Y, Le TK, Shaw JW, Kotapati S
ClinicoEconomics and Outcomes Research 2015, 7:397-407
Published Date: 21 July 2015
Relationship between patient dependence and direct medical-, social-, indirect-, and informal-care costs in Spain
Darbà J, Kaskens L
ClinicoEconomics and Outcomes Research 2015, 7:387-395
Published Date: 2 July 2015
Impact of noncommunicable diseases in the State of Qatar
Al-Kaabi SK, Atherton A
ClinicoEconomics and Outcomes Research 2015, 7:377-385
Published Date: 2 July 2015
Cost and effectiveness of omega-3 fatty acid supplementation in Chinese ICU patients receiving parenteral nutrition
Wu GH, Gao J, Ji CY, Pradelli L, Xi QL, Zhuang QL
ClinicoEconomics and Outcomes Research 2015, 7:369-375
Published Date: 26 June 2015
Association of persistent and transient worsening renal function with mortality risk, readmissions risk, length of stay, and costs in patients hospitalized with acute heart failure
Palmer JB, Friedman HS, Waltman Johnson K, Navaratnam P, Gottlieb SS
ClinicoEconomics and Outcomes Research 2015, 7:357-367
Published Date: 19 June 2015
Economic value of in vitro fertilization in Ukraine, Belarus, and Kazakhstan
Mandrik O, Knies S, Severens JL
ClinicoEconomics and Outcomes Research 2015, 7:347-356
Published Date: 12 June 2015
Medical costs associated with cardiovascular events among high-risk patients with hyperlipidemia
Bonafede MM, Johnson BH, Richhariya A, Gandra SR
ClinicoEconomics and Outcomes Research 2015, 7:337-345
Published Date: 9 June 2015
Relative cost-effectiveness of an extensively hydrolyzed casein formula containing the probiotic Lactobacillus rhamnosus GG in managing infants with cow's milk allergy in Italy
Guest JF, Panca M, Ovcinnikova O, Nocerino R
ClinicoEconomics and Outcomes Research 2015, 7:325-336
Published Date: 8 June 2015
Clinical trial simulation methods for estimating the impact of DPP-4 inhibitors on cardiovascular disease
Schuetz CA, Ong SH, Blüher M
ClinicoEconomics and Outcomes Research 2015, 7:313-323
Published Date: 5 June 2015
Comparative effectiveness and costs of generic and brand-name gabapentin and venlafaxine in patients with neuropathic pain or generalized anxiety disorder in Spain
Sicras-Mainar A, Rejas-Gutiérrez J, Navarro-Artieda R
ClinicoEconomics and Outcomes Research 2015, 7:299-312
Published Date: 4 June 2015
Evolution of health technology assessment: best practices of the pan-Canadian Oncology Drug Review
Rocchi A, Chabot I, Glennie J
ClinicoEconomics and Outcomes Research 2015, 7:287-298
Published Date: 3 June 2015
Prevalence and cost of imaging in inpatient falls: the rising cost of falling
Fields J, Alturkistani T, Kumar N, Kanuri A, Salem DN, Munn S, Blazey-Martin D
ClinicoEconomics and Outcomes Research 2015, 7:281-286
Published Date: 3 June 2015
Adherence to statin treatment following a myocardial infarction: an Italian population-based survey
Monaldi B, Bologna G, Costa GG, D'Agostino C, Ferrante F, Filice M, Grion A, Mingarelli A, Paloscia L, Tettamanti R, Veronesi C, Degli Esposti L
ClinicoEconomics and Outcomes Research 2015, 7:273-280
Published Date: 1 June 2015
Modeling the budget impact of long-acting injectable paliperidone palmitate in the treatment of schizophrenia in Japan
Mahlich J, Nishi M, Saito Y
ClinicoEconomics and Outcomes Research 2015, 7:267-272
Published Date: 22 May 2015
Application of a validated algorithm to estimate the effectiveness and cost of biologics for rheumatoid arthritis in the US pharmacy benefit manager context
Wu N, Bhurke S, Shah N, Harrison DJ
ClinicoEconomics and Outcomes Research 2015, 7:257-266
Published Date: 13 May 2015
Nab-paclitaxel, docetaxel, or solvent-based paclitaxel in metastatic breast cancer: a cost-utility analysis from a Chinese health care perspective
Dranitsaris G, Yu B, King J, Kaura S, Zhang A
ClinicoEconomics and Outcomes Research 2015, 7:249-256
Published Date: 12 May 2015
Cost-effectiveness of ranibizumab versus aflibercept in the treatment of visual impairment due to diabetic macular edema: a UK healthcare perspective
Régnier SA, Malcolm W, Haig J, Xue W
ClinicoEconomics and Outcomes Research 2015, 7:235-247
Published Date: 6 May 2015
A potential gender bias in assessing quality of life – a standard gamble experiment among university students
Al Obaidi L, Mahlich J
ClinicoEconomics and Outcomes Research 2015, 7:227-233
Published Date: 24 April 2015
Incorporating ulipristal acetate in the care of symptomatic uterine fibroids: a Canadian cost-utility analysis of pharmacotherapy management
Tsoi B, Blackhouse G, Ferrazzi S, Reade CJ, Chen I, Goeree R
ClinicoEconomics and Outcomes Research 2015, 7:213-225
Published Date: 17 April 2015
Inpatient cost of treating osteoporotic fractures in mainland China: a descriptive analysis
Yang YC, Du F, Ye WY, Chen Y, Li JH, Zhang J, Nicely H, Burge R
ClinicoEconomics and Outcomes Research 2015, 7:205-212
Published Date: 13 April 2015
Health economic evaluations of medical devices in the People's Republic of China: A systematic literature review
Zhang R, Modaresi F, Borisenko O
ClinicoEconomics and Outcomes Research 2015, 7:195-204
Published Date: 9 April 2015
Budget impact analysis of botulinum toxin A therapy for upper limb spasticity in the United Kingdom
Abogunrin S, Hortobagyi L, Remak E, Dinet J, Gabriel S, Bakheit AM
ClinicoEconomics and Outcomes Research 2015, 7:185-193
Published Date: 1 April 2015
The impact of chronic pain on direct medical utilization and costs in chronic obstructive pulmonary disease
Roberts MH, Mapel DW, Thomson HN
ClinicoEconomics and Outcomes Research 2015, 7:173-184
Published Date: 26 March 2015
Disability-adjusted life years lost due to diabetes in France, Italy, Germany, Spain, and the United Kingdom: a burden of illness study
Darbà J, Kaskens L, Detournay B, Kern W, Nicolucci A, Orozco-Beltrán D, Ramírez de Arellano A
ClinicoEconomics and Outcomes Research 2015, 7:163-171
Published Date: 23 March 2015
Annual biologic treatment cost for new and existing patients with moderate to severe plaque psoriasis in Greece [Corrigendum]
Fragoulakis V, Raptis E, Vitsou E, Maniadakis N
ClinicoEconomics and Outcomes Research 2015, 7:161-162
Published Date: 17 March 2015
Costs of illness analysis in Italian patients with chronic obstructive pulmonary disease (COPD): an update
Dal Negro RW, Bonadiman L, Turco P, Tognella S, Iannazzo S
ClinicoEconomics and Outcomes Research 2015, 7:153-159
Published Date: 16 March 2015
Cost-effectiveness of using an extensively hydrolyzed casein formula plus the probiotic Lactobacillus rhamnosus GG compared to an extensively hydrolyzed formula alone or an amino acid formula as first-line dietary management for cow’s milk allergy in the US
Ovcinnikova O, Panca M, Guest JF
ClinicoEconomics and Outcomes Research 2015, 7:145-152
Published Date: 27 February 2015
Health services financing and delivery: analysis of policy options for Dubai, United Arab Emirates
Hamidi S
ClinicoEconomics and Outcomes Research 2015, 7:133-143
Published Date: 25 February 2015
Medical resource utilization and costs associated with autosomal dominant polycystic kidney disease in the USA: a retrospective matched cohort analysis of private insurer data
Knight T, Schaefer C, Krasa H, Oberdhan D, Chapman A, Perrone RD
ClinicoEconomics and Outcomes Research 2015, 7:123-132
Published Date: 20 February 2015
Health economics, equity, and efficiency: are we almost there?
Ferraz MB
ClinicoEconomics and Outcomes Research 2015, 7:119-122
Published Date: 12 February 2015
Cost-utility of denosumab for the treatment of postmenopausal osteoporosis in Spain
Darbà J, Kaskens L, Sorio Vilela F, Lothgren M
ClinicoEconomics and Outcomes Research 2015, 7:105-117
Published Date: 9 February 2015
Estimating the real world daily usage and cost for exenatide twice daily and liraglutide in Germany, the Netherlands, and the UK based on volumes dispensed by pharmacies
McDonell AL, Kiiskinen U, Zammit DC, Kotchie RW, Thuresson PO, Nicolay C, Haslam T, Bruinsma M, Janszen-Van Oosterhout AJ, Otto T
ClinicoEconomics and Outcomes Research 2015, 7:95-103
Published Date: 30 January 2015
Economic evaluation of anti-TNF agents for patients with rheumatoid arthritis in Greece
Fragoulakis V, Vitsou E, Hernandez AC, Maniadakis N
ClinicoEconomics and Outcomes Research 2015, 7:85-93
Published Date: 16 January 2015
Annual biologic treatment cost for new and existing patients with moderate to severe plaque psoriasis in Greece
Fragoulakis V, Raptis E, Vitsou E, Maniadakis N
ClinicoEconomics and Outcomes Research 2015, 7:73-83
Published Date: 8 January 2015
End-stage renal disease in autosomal dominant polycystic kidney disease: a comparison of dialysis-related utilization and costs with other chronic kidney diseases
Brunelli SM, Blanchette CM, Claxton AJ, Roy D, Rossetti S, Gutierrez B
ClinicoEconomics and Outcomes Research 2015, 7:65-72
Published Date: 6 January 2015
Value analysis of digital breast tomosynthesis for breast cancer screening in a commercially-insured US population
Bonafede MM, Kalra VB, Miller JD, Fajardo LL
ClinicoEconomics and Outcomes Research 2015, 7:53-63
Published Date: 12 January 2015
Assessing the importance of predictors in unplanned hospital readmissions for chronic obstructive pulmonary disease
Yu TC, Zhou H, Suh K, Arcona S
ClinicoEconomics and Outcomes Research 2015, 7:37-51
Published Date: 6 January 2015
Cost of HAART in Italy: multicentric evaluation and determinants from a large HIV outpatient cohort
Tontodonati M, Cenderello G, Celesia BM, Trezzi M, Ursini T, Costantini A, Marra D, Polilli E, Catalani C, Butini L, Sozio F, Mazzotta E, Sciacca A, Rizzardini G, Manzoli L, Cozzi-Lepri A, Parruti G
ClinicoEconomics and Outcomes Research 2015, 7:27-35
Published Date: 22 December 2014
Cost–consequence analysis of long-term prophylaxis in the treatment of von Willebrand disease in the Italian context
Schinco P, Cultrera D, Valeri F, Borchiellini A, Mantuano M, Gorla F, Savarese A, Teruzzi C
ClinicoEconomics and Outcomes Research 2015, 7:17-25
Published Date: 17 December 2014
Economic evaluation of first-line and maintenance treatments for advanced non-small cell lung cancer: a systematic review
Chouaïd C, Crequit P, Borget I, Vergnenegre A
ClinicoEconomics and Outcomes Research 2015, 7:9-15
Published Date: 15 December 2014
The costs of fluid overload in the adult intensive care unit: is a small-volume infusion model a proactive solution?
Child DL, Cao Z, Seiberlich LE, Brown H, Greenberg J, Swanson A, Sewall MR, Robinson SB
ClinicoEconomics and Outcomes Research 2015, 7:1-8
Published Date: 15 December 2014